Numis Securities reiterated their under review rating on shares of Vernalis (LON:VER) in a research report report published on Wednesday morning.

Vernalis (VER) opened at GBX 5 ($0.07) on Wednesday. The firm has a market cap of $24.76 and a price-to-earnings ratio of -125.00. Vernalis has a 52 week low of GBX 4.08 ($0.06) and a 52 week high of GBX 26.25 ($0.36).

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at

About Vernalis

Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders.

Receive News & Ratings for Vernalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis and related companies with's FREE daily email newsletter.